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ABSTRACT
In Western countries, the incidence of testicular germ cell cancers (GCC) is 
steadily rising over the last decades. Mostly, men between 20 and 40 years of age 
are affected. In general, patients suffering from GCCs are treated by orchiectomy and 
radio- or chemotherapy. Due to resistance mechanisms, intolerance to the therapy 
or denial of chemo- / radiotherapy by the patients, GCCs are still a lethal threat, 
highlighting the need for alternative treatment strategies.
In this study, we revealed that germ cell cancer cell lines are highly sensitive 
to the histone deacetylase inhibitor romidepsin in vitro and in vivo, highlighting 
romidepsin as a potential therapeutic option for GCC patients.
Romidepsin-mediated inhibition of histone deacetylases led to disturbances of the 
chromatin landscape. This resulted in locus-specific histone-hyper- or hypoacetylation. 
We found that hypoacetylation at the ARID1A promotor caused repression of the SWI/
SNF-complex member ARID1A. In consequence, this resulted in upregulation of the 
stress-sensors and apoptosis-regulators GADD45B, DUSP1 and CDKN1A. RNAi-driven 
knock down of ARID1A mimicked in parts the effects of romidepsin, while CRISPR/
Cas9-mediated deletion of GADD45B attenuated the romidepsin-provoked induction 
of apoptosis and cell cycle alterations.
We propose a signaling cascade involving ARID1A, GADD45B and DUSP1 as 
mediators of the romidepsin effects in GCC cells.
INTRODUCTION
Testicular type II germ cell cancers arise from a 
common precursor lesion, termed germ cell neoplasia 
in situ (GCNIS) [1–3]. GCNIS cells are the result of a 
defective germ cell development, where a primordial germ 
cell (PGC) is thought to suffer from genetic aberrations 
leading to a developmental arrest [2, 4]. GCNIS cells 
eventually differentiate into the invasive type II germ cell 
cancers (GCCs), which are subdivided into seminomas 
and non-seminomas [2]. Seminomas are highly similar 
to GCNIS and PGCs regarding gene expression and 
histology [2]. Contrarily, the stem cell population of the 
non-seminomas, the embryonal carcinoma (EC) shows 
features of totipotency and is therefore able to differentiate 
into all three germ layers (teratomas) and extraembryonic 
tissues (yolk-sac tumors, choriocarcinomas).
Familial predisposition, environmental parameters 
like exposure towards fertilizers, fine dust, endocrine 
disruptors and hormones are discussed as risk factors 
for development of GCCs [5]. Additionally, presence 
of the testicular dysgenesis syndrome (cryptorchidism, 
azoospermia and testicular atrophy) increases the risk for 
GCC development [6, 7].
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Generally, GCCs are treated by orchiectomy and 
depending on stage with chemo- or radiotherapy in 
addition. Early stage seminomas are very radiosensitive. 
Thus, stage I - IIb seminomas are treated by radiotherapy, 
whereas non-seminomas are treated with chemotherapy. 
More advanced stages of seminoma or patients that do 
not tolerate radiotherapy also receive chemotherapy. 
Although most GCCs are sensitive towards a cisplatin-
based therapy, approximately 20 - 50% of patients 
with metastatic disease cannot be cured by standard 
chemotherapy due to resistance mechanisms [8]. Thus, 
there is a strong need for new therapeutic options to 
treat cisplatin-resistant disease. In this study, we treated 
GCC lines with the histone deacetylase inhibitor (HDI) 
romidepsin (ISTODAX, FK228, FR901228) to elaborate 
on the molecular mechanism and to address the question 
whether it is a therapeutic option for GCCs.
RESULTS
We reported previously that treatment of seminoma-
like TCam-2 cells with romidepsin rapidly induced 
apoptosis [9]. Based on this initial finding, we asked if 
romidepsin might also be toxic to other GCC cell lines. 
Thus, in this study we analyzed its molecular mode of 
action in vitro and in vivo and elaborated on the potential 
of romidepsin as a new therapeutic for GCCs.
We utilized GCC cell lines and corresponding 
cisplatin-resistant subclones. The cell line TCam-2 was 
used as a proxy for a seminoma, while the three cell 
lines 2102EP, NCCIT and NT2/D1 were derived from 
ECs and the two cell lines JAR and JEG-3 resemble 
a choriocarcinoma in culture [10–14]. As controls we 
included human primary fibroblasts (MPAF, ARZ, EMF) 
and the Sertoli cell line (FS1) [15].
Romidepsin efficiently kills GCC cells in vitro 
and in vivo
First, we treated seminoma-like TCam-2, the EC cell 
lines 2102EP and NCCIT as well as the choriocarcinoma-
like JAR and JEG-3 cells with various concentrations (1 
- 80 nM) of romidepsin for 24h and measured viability 
by a XTT assay (Supplementary Figure S1A). For 
comparison, cells were also treated with other HDIs (TSA, 
VPA, SAHA) and cisplatin. Romidepsin reduced viability 
starting from ≥ 5 nM, while VPA, SAHA and cisplatin had 
no detectable effect on viability at concentrations applied 
(Supplementary Figure S1A). Besides romidepsin, only 
TSA reduced viability of analyzed cell lines, but at much 
higher doses compared to romidepsin.
To determine the minimal effective concentration 
of romidepsin, we treated GCC cell lines once with 
1 - 10 nM romidepsin and measured the effects on cell 
viability by XTT assays for 96h (Figure 1). While 1 
nM had negligible effects on cell viability, a single 
application ≥ 2 nM strongly reduced viability in a dose-, 
time- and cell line-dependent manner within 4 days 
(Figure 1). These analyses demonstrate that GCC lines are 
highly susceptible to romidepsin treatment.
Figure 1: XTT assays of indicated GCC cell lines 24 - 96h after application of 1 - 10 nM romidepsin. Standard deviation 
is given above each data point.
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Next, we analyzed whether romidepsin kills 
GCC cells in an in vivo tumor model. To mimic GCCs, 
we xenografted 2102EP, 2102EP-R, NCCIT and 
NCCIT-R cells into the flank of nude mice and allowed 
tumors to grow for two weeks (-R = cisplatin-resistant 
subclone). Afterwards, we applied romidepsin (2 mg/kg) 
intravenously three times a week and monitored tumor 
growth for 10 days. Lately after 7 days, tumor sizes were 
significantly reduced in romidepsin treated mice compared 
to the control mice (Figure 2). We confirmed induction of 
apoptosis by detection of PARP cleavage in romidepsin 
treated mice bearing 2102EP-R and NCCIT-R tumors 
(Supplementary Figure S1B). In conclusion, romidepsin 
efficiently kills tumor cells in vivo by inducing apoptosis.
GCC cells mainly utilize HDAC1 for histone 
deacetylation
Next, we were interested in alterations of molecular 
mechanisms induced by romidepsin in GCCs. HDIs 
like Romidepsin inhibit histone deacetylases (HDACs). 
Re-analyzing an expression microarray of GCC tissues 
published in a previous study [12] and a qRT-PCR 
analysis of GCC cell lines revealed that HDAC1 is 
highly expressed in all GCCs, GCC cell lines, human 
fibroblasts (ARZ, MPAF) and the Sertoli cell line (FS1) 
(Supplementary Figure S1C, S1D). All other analyzed 
HDACs showed a lower expression compared to HDAC1 
in all analyzed GCC samples (Supplementary Figure S1C, 
S1D), indicating that GCCs might mainly utilize HDAC1 
for histone deacetylation.
Romidepsin causes hyperacetylation of histones 
H3 and H4
Since inhibition of HDACs should lead to histone 
hyperacetylation, we analyzed the pan-acetylation status 
of histones 3 and 4 (pan-H3ac / -H4ac) 2 - 16h after 10 nM 
romidepsin treatment of GCC cell lines, fibroblasts and the 
Sertoli cell line FS1. As shown by western blotting, within 
2 - 16h after treatment H3 and H4 became hyperacetylated 
in all samples analyzed (Supplementary Figure S2A, 
S2B). In parallel, an ELISA-based quantification 
method revealed strong reduction of HDAC activity in 
protein lysates of TCam-2 and NCCIT cells 4 - 16h after 
romidepsin application (Supplementary Figure S2C). So, 
romidepsin reduced the activity of HDACs, leading to 
pan-H3 / H4 hyperacetylation.
Romidepsin induces apoptosis and affects the 
cell cycle in vitro
Our XTT assays demonstrated that GCC cell 
lines display reduced proliferation / viability rates after 
romidepsin application. A PI-FACS analysis 16h after 
romidepsin treatment found a strong enrichment of GCC 
and fibroblast (MPAF, ARZ) cells in G2/M-phase of the 
cell cycle, while FS1 cells enriched in the G1/G0-phase 
(Figure 3A). Thus, GCC cell lines enrich in G2/M-phase 
of the cell cycle in response to romidepsin, which might 
be indicative of a G2-arrest.
Apoptosis was detected by a FACS-based AnnexinV 
/ 7AAD analysis. Induction of apoptosis was seen in GCC 
Figure 2: Measurement of the tumor burden during treatment of xenografted 2102EP(-R) and NCCIT(-R) cells with 
2.5 mg/kg romidepsin or the solvent for 10 days. Inlay: photos of tumors of solvent (left) and romidepsin (right) treated mice after 
10 days. n. s. = not significant, p-value > 0.05; asterisk = significant, p-value < 0.05.
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cells treated with romidepsin (TCam-2, 2102EP(-R), 
NCCIT(-R), NT2/D1(-R) and JAR), while no apoptosis 
was observed in fibroblasts or the Sertoli cell line (Figure 
3B). FAS and APAF1 are markers for the death-receptor and 
intrinsic mitochondrial apoptosis pathway, respectively. 
FAS was only slightly deregulated in GCC cell lines, 
while APAF1 was strongly upregulated in all GCC cell 
lines after romidepsin application (Figure 3C, 3D). This 
suggests that in response to romidepsin all GCC cells 
mainly induce apoptosis via the intrinsic mitochondrial 
Figure 3: A, B. FACS-based cell cycle (A) and apoptosis (B) analysis of GCC cell lines, fibroblasts and FS1 cells 16 / 24h after 10 nM 
romidepsin application. C, D. qRT-PCR analysis of FAS / APO-1 and APAF1 in GCC cell lines, fibroblasts and FS1 cells 2 - 16h after 10 
nM romidepsin treatment. Inlays: averaged expression changes over time (GCC cell lines only). E. PathScan analysis of indicated signaling 
molecules in GCC cell lines treated with 10 nM romidepsin for 4 and 16h. F, G. qRT-PCR analysis of P53 and CDKN1A in GCC cell lines, 
fibroblasts and FS1 cells 2 - 16h after 10 nM romidepsin treatment. Inlays: averaged expression changes over time (GCC cell lines only). 
H. Western blot analysis of MAPK signaling factors in GCC cells and fibroblasts 16h after 10 nM romidepsin treatment. I. Densiometric 
evaluation of western blot data (Supplementary Figure S3G) of pRPS6 in GCC cell lines 16h after 10 nM romidepsin treatment.
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pathway. Importantly, a strong downregulation of FAS and 
a nearly unchanged APAF1 expression was found in all 
control cells (MPAF, ARZ, FS1), matching the observation 
that these cells do not initiate apoptosis in response to the 
concentrations of romidepsin, which are cytotoxic for 
GCC cell lines (Figure 3B, 3C, 3D).
Alterations in signaling pathways in response to 
romidepsin
We performed a PathScan array, which detects 
the phosphorylation or cleavage status of 18 signaling 
molecules to identify signaling pathways activated by 
romidepsin (Supplementary Figure S3A). In all cell lines 
analyzed (TCam-2, 2102EP, NCCIT, JAR), we found a 
strong induction of PARP cleavage (Asp214) 16h after 
romidepsin application, further confirming induction of 
apoptosis (Figure 3E). By western blotting we verified 
cleavage of PARP in romidepsin treated TCam-2 cells, 
while no cleavage was found in fibroblasts, further 
suggesting that romidepsin does not induce apoptosis in 
fibroblasts (Supplementary Figure S3B).
Additionally, we detected nearly unchanged 
phosphorylation (p) of P53 (Ser15) after romidepsin 
treatment (Figure 3E). Further to very low levels of 
pP53 (Figure 3E), we detected downregulation of P53 
expression in all analyzed cell lines, while the P53 
downstream effector CDKN1A was strongly upregulated 
(except in JEG-3) (Figure 3F, 3G). CDKN1A upregulation 
was verified by western blotting in TCam-2, JAR and 
MPAF (Supplementary Figure S3C). By qRT-PCR 
analysis, we confirmed that the cisplatin-resistant GCC 
cell lines also upregulated CDKN1A, while P53 was 
downregulated (2102EP-R) or remained unchanged 
(NCCIT-R, NT2/D1-R) (Supplementary Figure S3D). 
These findings confirm previous findings demonstrating 
that GCC cell lines induced CDKN1A in a P53-
independent manner [16]. In P53-deficient human colon 
cancer cells CDKN1A induction is associated with G2/M-
phase arrest [17]. Thus, upregulation of CDKN1A might 
contribute to enrichment of the cells in G2/M-phase after 
romidepsin application.
We found strongly reduced pERK1/2 (Thr202/
Tyr204) levels in all GCC cells by the PathScan array 
(Figure 3E) and confirmed this finding by western 
blot analysis of TCam-2 and 2102EP cells (Figure 3F). 
Additionally, all analyzed cell lines showed reduced 
phosphorylation of the ERK1/2 signaling downstream 
target ribosomal protein S6 (RPS6; Ser235/Ser236) 
(Figure 3E, 3G; Supplementary Figure S3B). Decreased 
pRPS6 is associated with growth arrest. Thus, romidepsin 
treatment leads to a diminished pERK1/2 activity, resulting 
in reduced pRPS6 levels, which might contribute to the 
alterations in the cell cycle, i. e. enrichment in G2/M-
phase.
Dynamics of histone acetylation and gene 
expression in response to romidepsin
Since romidepsin inhibits HDACs, leading to 
histone hyperacetlyation, we performed ChIP-seq. against 
pan-H3ac in romidepsin / solvent treated TCam-2 to 
analyze the changes in detail. Pooled input DNA was used 
as control. In total, 8907 loci showed an at least 2-fold 
change in pan-H3ac occupation upon treatment with 
romidepsin compared to the solvent control (881 loci 
increased in pan-H3ac, 8026 loci decreased in pan-H3ac) 
(Supplementary Data S1A). These results demonstrate 
that a large number of loci seem to escape the global 
hyperacetylation induced by chromatin-wide inhibition of 
HDACs by romidepsin.
To analyze, whether the changes in acetylation 
caused by romidepsin correspond to changes in gene 
expression we next performed an expression microarray 
analysis of TCam-2 cells treated with 10 nM romidepsin 
for 8 and 16h (Supplementary Data S1B, S1C). 
Surprisingly, only 197 genes were upregulated and 125 
genes were downregulated (≥ 2-fold) 16h after romidepsin 
application (Supplementary Data S1C). 16 of the 197 
upregulated genes showed an increase in H3ac upon 
romidepsin treatment, while 84 of the 125 downregulated 
genes became hypoacetylated (Supplementary Data S1A). 
These findings suggest that the expression of a small 
fraction of genes is affected by romidepsin-mediated 
HDAC inhibition.
Genes commonly deregulated upon romidepsin 
treatment in GCCs
To identify genes commonly deregulated in response 
to romidepsin, we extended our expression microarray 
analysis to 2102EP, NCCIT and JAR cells treated with 
10 nM romidepsin for 8 and 16h (Supplementary Data 
S1B, S1C). In general, the number of deregulated genes 
increased from 8 to 16h after treatment and more genes 
were upregulated than downregulated (Supplementary 
Figure S4A). A Venn diagram (Figure 4A) shows that 2 
genes (DHRS2, GADD45B) were commonly upregulated 
between the GCC cells 8h after romidepsin application, 
while 27 genes were deregulated after 16h (23 upregulated, 
4 downregulated) (fold change (FC) ≥ Log22) (Figure 4A, 
4B; Supplementary Data S1D).
From the 23 upregulated genes, four genes (BAIAP2, 
DNAJB1, MKNK2, SLC9A1) showed increased H3ac 
levels upon romidepsin treatment of TCam-2 cells (Figure 
4B; Supplementary Data S1A). Additionally, two of the 
four downregulated genes (ARID1A, ZMYND11) showed 
a decrease of H3ac in romidepsin treated TCam-2 (Figure 
4B; Supplementary Data S1C, S1D).
As already demonstrated, CDKN1A was 
upregulated in all analyzed cell lines (FC ≥ Log21,5 ≤ 
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Figure 4: A. Venn diagrams of commonly expressed genes between GCC cell lines 8 and 16h after romidepsin treatment as found 
by expression microarray analysis. B. Expression levels of the 27 commonly deregulated genes (23 upregulated, 4 downregulated) in 
GCC cell lines. C. qRT-PCR verification of selected deregulations in romidepsin treated (16h) GCC cell lines. D, E. STRING protein-
protein-interaction prediction of the 23 upregulated genes (D) and 4 downregulated genes (E). An extended network, including CDKN1A 
is illustrated in the red box (D).
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Log22) (Supplementary Data S1E). We further verified 
upregulation of DHRS2, RHOB, GADD45B, ATF3, 
DUSP1, FOS and ID2 in GCC cell lines (Figure 4C). By 
western blotting, we verified upregulation of GADD45B 
in 2102EP, NCCIT and JAR cells as well as upregulation 
of ID2 in 2102EP-R, NCCIT-R and NT2/D1-R 
(Supplementary Figure S3E).
A STRING analysis of the 23 upregulated genes 
predicted interaction of the stress-sensors DUSP1, 
GADD45B, ATF3 as well as the immediate early gene 
FOS and the ring finger protein ZFP36, suggesting that 
this network mediates the romidepsin-provoked stress- 
and apoptosis-response (Figure 4D). When manually 
including CDKN1A to the dataset, the interaction network 
was extended to CDKN1A and ID2 (Figure 4D, inlay). 
H3ac levels across the gene bodies of these romidepsin-
response genes (ATF3, DUSP1, FOS, GADD45B, ID2, 
ZFP36, CDKN1A) were already high in the solvent control 
and did not increase further under romidepsin treatment 
of TCam-2 cells (Supplementary Figure S3F). Thus, 
these data show that upregulation of these genes occurs 
independent of euchromatin formation.
On the other hand, STRING analysis of 
downregulated genes predicted interaction of ARID1A 
and ZMYND11 with members of the ATP-dependent SWI/
SNF-chromatin-remodeling-complex (SMARCs) (Figure 
4E). As mentioned before, in TCam-2 cells downregulation 
of ARID1A  correlates to decreasing H3ac levels at the 
promotor under romidepsin treatment (Supplementary 
Data S1A). So downregulation of ARID1A seems to be 
the result of heterochromatin formation.
Upon romidepsin application, the EC cell lines 
2102EP and NCCIT cells tended to downregulate EC-, 
self-renewal- and pluripotency-associated genes NANOG, 
OCT3/4, SOX2, DPPA3, DPPA4, GDF3, LIN28A, ZFP42, 
SALL4, PRDM14, ZIC3, UTF1, DNMT3B, BCAT1, 
SPRY4, YAP1 and NODAL (only 2102EP) (Supplementary 
Data S1D). Choriocarcinoma-like JAR cells 
downregulated DPPA3, LIN28, ZFP42, SALL4, DNMT3L 
and YAP1. TCam-2 cells showed downregulation of 
NANOG, OCT3/4, DPPA4, GDF3, SPRY4, YAP1, 
UTF1 as well as LIN28 and further downregulated the 
seminoma-associated genes SOX17, IGF1 and PRDM1 
(Supplementary Data S1D). In TCam-2, downregulation 
of IGF1, DPPA4, SPRY4, YAP1 and ZSCAN10 correlated 
to decreasing H3ac levels at corresponding genomic 
loci, suggesting that expression of these factors might be 
silenced by heterochromatin formation (Supplementary 
Data S1A). These findings demonstrate that romidepsin 
application results in downregulation of pluripotency-
related genes and EC / seminoma markers in TCam-2 and 
non-seminomatous GCC cells.
To measure the genome-wide effects of romidepsin 
on gene expression of our control cells, we performed 
a microarray analysis of fibroblasts and the Sertoli cell 
line FS1 8 and 16h after 10 nM romidepsin treatment. In 
general, control cells seemed less affected by a romidepsin 
treatment since only little changes in gene deregulation 
could be detected (Supplementary Figure S4A vs. S4B). 
We found significant deregulation of 12 (8h) and 47 
(16h) genes in both fibroblast cultures (FC ≥ Log22) 
(Supplementary Figure S4C, Supplementary Data S1F). 
We detected a common deregulation of 3 genes after 8h 
and 37 genes after 16h between fibroblasts and FS1 cells 
(Supplementary Figure S4C, Supplementary Data S1G). 
A comparison of the genes deregulated in fibroblasts and 
FS1 to the set of genes deregulated in GCC cell lines 
revealed a common upregulation of 4 genes (DHRS2, 
RHOB, CRISPLD2, BAIAP2) (Supplementary Figure S4C, 
Supplementary Data S1H). STRING analysis however 
could not predict any interaction between those 4 genes 
(Supplementary Data S1H). We verified upregulation of 
DHRS2 and RHOB expression in fibroblasts, FS1 and 
GCC cells by qRT-PCR analysis (Supplementary Figure 
S4D).
ARID1A is an important mediator of the 
romidepsin response in GCC cell lines
Our microarray analysis demonstrated that ARID1A, 
a member of the chromatin-remodelling SWI/SNF-
complex is strongly downregulated upon romidepsin 
treatment of GCC cells. Additionally, the ChIP-seq 
analysis suggested that a decrease in acetylation of the 
chromatin covering the ARID1A promotor might repress 
ARID1A expression (Figure 5A, red box). The SWI/SNF-
complex is involved in induction of cellular senescence 
and apoptosis as well as in oncogenesis and is required 
for transcriptional activation or repression of genes by 
chromatin-remodelling [18]. Thus, downregulation of 
the SWI/SNF-complex member ARID1A might influence 
chromatin-remodeling processes, resulting in altered 
transcription and DNA synthesis rates. So we analyzed 
the role of ARID1A in the molecular cascade of the 
romidepsin response in more detail.
First, we knocked down ARID1A by siRNA in 
TCam-2 cells and analyzed the expression of factors 
identified in this study. We achieved a strong ARID1A 
knock down 24 and 48h after transfection (ca. 70%), while 
72h post transfection, ARID1A mRNA levels recovered to 
35% (Figure 4B). Reduction of ARID1A protein levels 
was verified by western blot analysis (Figure 4B). 24 - 48h 
after knockdown, we detected upregulation of GADD45B, 
DUSP1, FOS, ATF3, DHRS2, RHOB, ID2 and CDKN1A, 
while levels of ZMYND11 SMARCA4 and SMARCB1 
remained unchanged (Figure 5B). After 72h expression 
levels of these factors began to normalize, correlating to 
recovering ARID1A mRNA levels.
We confirmed these results by transducing TCam-2 
cells with four different ARID1A shRNA constructs and 
measured changes in gene expression after eight days 
(Supplementary Figure S5A). Efficient downregulation 
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of ARID1A was demonstrated by qRT-PCR and western 
blot analysis, respectively (Supplementary Figure S5A). 
Again, we found upregulation of GADD45B, DUSP1, 
FOS, ATF3, DHRS2, RHOB, ID2 and CDKN1A as well as 
unchanged P53 expression. In conclusion, downregulation 
of ARID1A during a romidepsin treatment contributes to 
upregulation of stress, cell cycle and apoptosis regulators.
Of note, pluripotency in murine embryonic stem 
cells is maintained by SWI/SNF-complex activity and its 
component ARID1A contributes to proper expression of 
OCT3/4, SOX2 and UTF1 [19]. Vice versa, pluripotency 
factors, like NANOG, GDF3, OCT3/4 and SOX2 interact 
with SWI/SNF-complex members and influence higher 
order chromatin structure at pluripotency-associated gene 
Figure 5: A. H3ac levels across the ARID1A gene as illustrated by the ‘UCSC Genome Browser’. The red box highlights the promotor 
region. B. qRT-PCR and western blot analysis (inlay) of indicated genes 24 - 72h after ARID1A siRNA transfection of TCam-2 cells. C. 
qRT-PCR analysis of indicated genes in parental and GADD45B-deficient TCam-2 cells 16h after treatment with romidepsin. Samples were 
normalized to corresponding solvent controls. D. qRT-PCR analysis of GADD45B and CDKN1A in TCam-2 cells transiently overexpressing 
GADD45B cDNA (1: 0.75 μg plasmid transfected, 2: 1 μg plasmid transfected). E, F. Annexin / 7AAD- (E) and PI-FACS (F) analysis of 
apoptosis and cell cycle distribution 16h after romidepsin treatment of TCam-2 and TCam-2-ΔGADD45B (-ΔGADD45B) cells. p-values 
were calculated by two-tailed Student’s t-test and are given above the bars (* = significant; p-value < 0.05).
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promotors [20]. After romidepsin treatment, we detected 
downregulation of pluripotency factors in the EC lines 
2012EP and NCCIT as well as the seminoma-like TCam-
2 (Supplementary Data S1E). In TCam-2 cells, an ARID1A 
shRNA-mediated knock down resulted in downregulation 
of NANOG, OCT3/4, LIN28 and GDF3 expression 
and H3ac levels strongly decreased in pluripotency-
associated gene promotors upon romidepsin application 
(Supplementary Figure S5B, S5C). Thus, we postulate that 
ARID1A supports the expression of pluripotency factors in 
GCC cell lines.
GADD45B contributes to induction of apoptosis 
and affects the cell cycle
Upon cellular stress, GADD45B induces apoptosis 
and growth arrest [21]. GADD45B is upregulated in 
romidepsin treated GCC cells and after ARID1A knock 
down in TCam-2 cells (this study). So, does GADD45B 
contribute to induction of apoptosis and cell cycle 
alterations in response to romidepsin? Here, we established 
five GADD45B-deficient TCam-2 clones (TCam-2-
ΔGADD45B1 - 5) by the gene-editing CRISPR/Cas9 
technique (Supplementary Figure S5D). Three clones (1, 
2, 4) displayed a 157 bp and a 518 bp band in a genotyping 
PCR, indicating that CRISPR/Cas9-mediated gene-editing 
resulted in a 902 bp and a 541 bp deletion, respectively. 
Two clones (3, 5) displayed a 541 bp deletion on both 
alleles. No band corresponding to the wildtype GADD45B 
locus was found in the TCam-2-ΔGADD45B clones. 
These data validate successful deletion of GADD45B in 
the TCam-2-ΔGADD45B clones.
A qRT-PCR analysis after treatment with romidepsin 
demonstrated induction of GADD45B in the parental 
TCam-2 cells and no expression in TCam-2-ΔGADD45B 
clones (Figure 5C). Interestingly, in TCam-2-ΔGADD45B 
cells upregulation of CDKN1A is only half the level 
compared to parental TCam-2 cells.
Further overexpression of GADD45B in TCam-2 
cells by transfecting two different amounts of a GADD45B 
cDNA-coding plasmid (1: 0.75 mg, 2: 1 mg) resulted in 
a dose dependent upregulation of CDKN1A (Figure 5D). 
These data suggest that GADD45B contributes to the 
upregulation of CDKN1A. Notably, expression levels 
of the other stress sensors and apoptosis as well as cell 
cycle regulators remained unchanged between parental 
TCam-2 and TCam-2-ΔGADD45B clones, suggesting 
that GADD45B has no influence on the expression of these 
factors (Figure 5C).
We asked if GADD45B-deficiency attenuates 
romidepsin-induced apoptosis and cell cycle alterations. 
Indeed, an Annexin V / 7AAD-FACS analysis 
demonstrated that the percentage of apoptotic cells is 
significantly lower in TCam-2-ΔGADD45B clones 16h 
after romidepsin treatment (1.75% more compared to 
solvent control) than in parental TCam-2 cells (6.4% more 
compared to solvent control (Figure 5E). Additionally, 
16h after romidepsin treatment a PI FACS demonstrated 
that only 4.6% of TCam-2-ΔGADD45B cells enriched 
in G2/M-phase of the cell cycle (compared to solvent 
control), while 15.3% of the parental TCam-2 enriched 
in G2/M-phase (compared to solvent control) (Figure 
5F). Thus, GADD45B seems to contribute to induction of 
apoptosis and enrichment in G2/M-phase of the cell cycle 
in response to romidepsin. Parts of these effects might be 
mediated by CDKN1A.
Deregulations in gene expression found in vitro 
are reflected in vivo
Finally we asked, if the results gathered in our 
in vitro experiments are also reflected in vivo. Thus, 
we xenografted 2102EP, NCCIT and JAR cells into 
the flank of nude mice and led tumors grow for two 
weeks. Afterwards, romidepsin (10 mg/kg) was injected 
intravenously and tumors were recovered after 8 and 
24h. A qRT-PCR analysis demonstrates that the same 
genes were deregulated in expression as found in vitro 
(Figure 6A). In addition, histones H3 and H4 became 
hyperacetylated (Figure 6B). So, the effects caused by 
romidepsin are highly comparable in vitro and in vivo and 
conclusions drawn from our in vitro studies can reliably be 
transferred to the in vivo situation.
DISCUSSION
In this study, we demonstrated that romidepsin is 
highly toxic at low concentrations to GCC cells in vitro 
and in vivo. Romidepsin led to a disturbed chromatin 
landscape, resulting in hyper- and hypoacetylation of the 
histones. H3-hypoacetylation at the ARID1A promotor 
leads to downregulation of ARID1A expression, resulting 
in upregulation of the stress-sensors GADD45B and 
DUSP1.
Based on our results, we propose a model of the 
molecular mechanisms of romidepsin in GCC cells 
(Figure 7). Downregulation of ARID1A in response to 
romidepsin induces expression of stress-sensors and 
apoptosis as well cell cycle regulators (GADD45B, 
ATF3, FOS, ZFP36, DUSP1, ID2 and CDKN1A). We 
demonstrated that the stress-sensor GADD45B contributes 
to CDKN1A upregulation, induction of apoptosis and 
G2/M-phase enrichment. The immediate early gene and 
MAKP signaling inhibitor DUSP1 is induced in response 
to environmental stress and romidepsin [22] (this study). 
We hypothesize that in response to romidepsin DUSP1 
mediated repression of the ERK1/2 signaling cascade 
leads to reduced phosphorylation of P90 ribosomal S6 
kinase (RSK), which in consequence results in diminished 
pRPS6 levels [23]. Reduction of ERK1/2 signaling and 
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Figure 6: A. qRT-PCR analysis of 2102EP, NCCIT and JAR tumor tissues. Cells were xenografted for 2 weeks and then treated for 8 and 
24h with 10 mg/kg romidepsin i. v. B. Western blot analysis of pan-H3ac / H4ac in 2102EP, NCCIT and JAR tumor tissues treated with 10 
mg/kg romidepsin for 8 and 24h.
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pRBS5 levels are associated with growth arrest and 
apoptosis [23, 24]. These effects are summarized in our 
model and synergistically contribute to induction of stress, 
apoptosis and enrichment of romidepsin treated cells in the 
G2/M-phase of the cell cycle (Figure 7).
Importantly, the molecular effects found in vitro, 
like upregulation of stress- and apoptosis-regulators, 
cleavage of PARP and hyperacetylation of histones H3 and 
H4 were also found in tumors from xenografted GCC cell 
lines. Thus, we postulate that we molecular mode of action 
is highly similar in vitro and in vivo.
Our study demonstrates that romidepsin seems to be 
an interesting treatment option, especially for metastasized 
and / or cisplatin-resistant GCCs.
Figure 7: Model summarizing the molecular mode of action of romidepsin in GCCs. Arrow = ‘activation / induction’, 
T-shaped arrow = ‘inhibition / repression’, dashed arrows = ‘abolished interaction’, Ac = acetylation, H3 / H4 = histones 3 and 4.
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MATERIALS AND METHODS
Cell culture
All GCC cell lines used in this study were cultivated 
as described previously [14]. 2102EP-R, NCCIT-R and 
NT2/D1-R were cultivated as their corresponding parental 
cell lines. MPAF, ARZ and EMF (provided by Dr. Michael 
Peitz (Life & Brain, Department of Reconstructive 
Neurobiology, Bonn)) as well as FS1 (provided by Valerie 
Schumacher, [15]) were grown in DMEM medium (10% 
FCS (20% FS1), 1% Penicillin / Streptomycin, 200 mM 
L-Glutamine, 1x non-essential amino acids, 100 nM 
ß-Mercaptoethanol) at 37°C and 5% CO2.
GCC and testis tissues
Seminoma (n = 4) and EC (n = 2) tissues as well 
as normal testis tissue were obtained from the Institute of 
Pathology (University Medical School, Bonn, Germany).
An internal review board allowed the use of these 
tissues in context of this study. Written permission to use the 
tissue for scientific purposes was obtained from the patients 
and was approved by the ‘ethics committee for clinical 
trials on humans and epidemiological research with patient-
related data of the medical faculty of the Rheinischen- 
Friedrich-Wilhelms-University Bonn’. No personal patient 
data will be collected or stored in this study.
HDI application
Romidepsin was dissolved in dimethyl sulfoxide 
(DMSO; AppliChem GmbH, Darmstadt, Germany) 
and diluted in phosphate buffered saline (PBS) to a 
stock solution of 4.62 mM. Romidepsin was provided 
by Gloucester Pharmaceuticals (Celgene, Signal 
Pharmaceuticals, LLC, San Diego, CA, USA; MTA 
ID #CC0488464). SAHA and TSA (both from Sigma-
Aldrich, Taufkirchen, Germany) were diluted in DMSO 
to 94.5 mM and 500 μM, respectively. VPA (Sigma-
Aldrich) was diluted in H2O (dest.) to a 301 μM stock 
solution and cisplatin (Sigma-Aldrich) was diluted in 
dimethylformamide (DMF; Merck, Darmstadt, Germany) 
to 41.65 mM.
RNA and protein isolation
Total RNA and proteins were isolated as described 
previously [14]. Briefly, RNA was isolated by the 
RNAeasy mini kit (Qiagen, Hilden, Germany) and 
proteins by RIPA buffer.
Western blot
Western blots were performed as described 
previously [14]. Beta-ACTIN was used as housekeeper 
and loading control. See Table 1 for antibody details.
Quantitative RT-PCR
Quantitative RT-PCR (qRT-PCR) was performed 
as published previously [14]. 500 ng of total RNA was 
used for first strand synthesis (FSS). GAPDH was used as 
housekeeping gene and for data normalization. See Table 
2 for primer sequences.
siRNA and cDNA transfection
Transfection of TCam-2 cells with siRNA or a 
cDNA-coding plasmid was performed as described 
previously [9]. Briefly, 1x105 cells were seeded onto 
6-well plates 24h before transfection. For transfection, 
FuGeneHD (Promega, Mannheim, Germany) was used at 
a ratio of 5: 1 (e.g. 5 μl FuGeneHD: 1 μg siRNA). ARID1A 
siRNAs were obtained from Santa Cruz Biotechnology as 
a pool of three different siRNAs (Santa Cruz, Heidelberg, 
Table 1: Antibodies used in this study
Antibody Company Clone / Order No. Western Blot
ARID1A Cell signaling D2A8U / 12354 1:500
Beta-Actin Sigma-Aldrich AC-15 1:20000
CDKN1A Santa Cruz C-19 / sc-397 1:500
cleaved PARP Abcam ab4830 1:500
GADD45B Sigma-Aldrich AV48346 1:1000
H3 pan-acetylation Active motif 39139 1:500
H4 pan-acetylation Active motif 39243 1:750
ID2 Cell signaling D39E8 / 3431 1:500
phospho-ERK1/2 Cell signaling 197G2 / 4377 1:1000
total-ERK1/2 Cell signaling 9102 1:5000
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Table 2: Oligonucleotides used in this study
Gene Forward primer Reverse primer Tan Cycles
APAF1 ACAATGCTCTACTACATGAA GGATATAAAGA CACTGGAAGAAGAGACAACAGGAA 60°C 40
ARID1A TCTTGCCCATCTGATCCATT CCAACAAAGGAGCCACCAC 60°C 40
ATF3 AAGAACGAGAAGCAGCATTTGAT TTCTGAGCCCGGACAATACAC 60°C 40
CDKN1A CCTCATCCCGTGTTCTCCTTT GTACCACCCAGCGGACAAGT 60°C 40
DHRS2 CTCCATGTAGGGCAGCAACT GTAGGGAGCACTCTGGGGAC 60°C 40
DUSP1 GTACATCAAGTCCATCTGAC GGTTCTTCTAGGAGTAGACA 60°C 40
FAS / APO-1 AGCTTGGTCTAGAGTGAAAA GAGGCAGAATCATGAGATAT 60°C 40
FOS GAGAGCTGGTAGTTAGTAGCATGTTGA AATTCCAATAATGAACCCAATA GATTAGTTA 60°C 40
GADD45B GTCGGCCAAGTTGATGAAT CACGATGTTGATGTCGTTGT 60°C 40
GADD45B 
genotyp. CCCGTCACTGATCCCTCTTT CTACTGCGAAGAAAGCCGG 55°C 35
GAPDH TGCCAAATATGATGACATCAAGAA GGAGTGGGTGTCGCTGTTG 60°C 40
HDAC1 TAAATTCTTGCGCTCCATCC AACAGGCCATCGAATACTGG 60°C 40
HDAC2 CGTGTAATGACGGTATCATTCC ACCAGATAATGAGTCTGCACC 60°C 40
HDAC3 CTGTGTAACGCGAGCAGAAC GCAAGGCTTCACCAAGAGTC 60°C 40
ID2 TCAGCCTGCATCACCAGAGA CTGCAAGGACAGGATGCTGATA 60°C 40
P53 TTGCAATAGGTGTGCGTCAGA AGTGCAGGCCAACTTGTTCAG 60°C 40
RHOB GGGACAGAAGTGCTTCACCT CGACGTCATTCTCATGTGCT 60°C 40
SMARCA4 CAGCATGCCAAGGATTTCAAG CGATCCGCTCGTTCTCTTTC 60°C 40
SMARCB1 AACGTCAGCGGGTTCAAAT GCCTTCACCTGGAACATGAA 60°C 40
ZMYND11 TTGTTAAACGTGCCATGACC GCATGTGTGGAGACAGAGGA 60°C 40
Gene shRNA sequence
ARID1A sh1 5’-TCGCCTCTATGTGTCTGTGAAGGAGATTG-3’
ARID1A sh2 5’-GCAAACTCAGCATCCAGGACAACAATGTG-3’
ARID1A sh3 5’-CCTTGCTGTCTCAGCAGCCAATCAACTTA-3’
ARID1A sh4 5’-CCATTTGTGGTGGACTGCTCAGATAACGT-3’
Gene gRNA sequence
GADD45B gRNA 1 5’-CACAGTGGGGGTGTACGAGT-3’
GADD45B gRNA 2 5’-ACAACGACATCAACATCGTG-3’
GADD45B gRNA 3 5’-CTCTTCCAGGCGTCCGTGTG-3’
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Germany). Scrambled siRNA was used as negative control 
and for data normalization (AllStars Negative Control 
siRNA; Qiagen). siRNA experiments were performed 
in biological triplicates (n = 3). The GADD45B cDNA-
coding plasmid was obtained from Origene (via Biocat, 
Heidelberg, Germany). The empty vector was used as 
negative control and for data normalization.
shRNA transduction
For retroviral transduction of TCam-2 cells, four 
different ARID1A shRNAs encoded in the pGFP-V-RS 
vector were utilized (Origene, via BioCat, Heidelberg, 
Germany). The empty vector was used as negative control 
and for data normalization. See Table 2 for the sequences 
of the oligonucleotides used for generation of the ARID1A 
targeting shRNA-expressing plasmids. Retroviral particles 
were produced in 1.2x106 HEK293 cells by transfecting 2 
μg of the retroviral shRNA, 2 μg pCMV-gag-pol-plasmid 
and 220 ng pCMV-VSV-G-plasmid via the calcium 
phosphate method. The next day, medium was replaced by 
fresh medium. On day 3, the supernatant was harvested, 
sterile filtered and applied to the target cells. ARID1A 
shRNA expressing cells were selected by adding 0.5 mg/
ml puromycin every second day for one week.
Establishment of GADD45B-deficient TCam-2 
cells by CRISPR/Cas9 gene-editing
Five different TCam-2-ΔGADD45B clones 
were generated as described previously [25]. Briefly, 
by using FuGeneHD (Promega) 1x105 TCam-2 cells 
were transfected simultaneously with the pX330 vector 
encoding for three different guide RNAs (gRNA) directed 
against the GADD45B locus (Santa Cruz) and a GFP-
coding plasmid. See Table 2 for gRNA sequences. Two 
days after the transfection, GFP-positive clones were 
manually picked and clonally expanded. Deletions within 
the coding sequence of GADD45B in each clone were 
detected by PCR (Supplementary Figure S5D). See Table 
2 for primers used for genotyping.
Measurement of HDAC activity
To measure the activity of HDACs we utilized the 
Epigentek ‘EpiQuik HDAC Activity / Inhibition Assay 
Kit’ (Epigentek, via Biocat). The procedure was performed 
as recommended in the manual. Whole protein lysates 
were prepared by NP-40 isolation buffer (150 mM sodium 
chloride, 1% NP-40, 50 mM Tris (pH 8)). 10 μg of protein 
was used for analysis.
XTT assay
For the XTT-assay (2,3-bis-(2-methoxy-4-nitro-5-
sulfophenyl)-2H-tetrazolium-5-carboxanilide), 24h before 
starting the experiment 5000 cells (8 x) were seeded in 100 
μl standard growth medium without phenol red per well of 
a 96-well plate. The next day, different concentrations of 
HDIs or corresponding solvents were added to the cells. 
At the desired time points, 50 μl XTT (1 mg/ml) plus 1 μl 
PMS (1.25 mM) (both from Sigma-Aldrich) were added 
and absorbance was measured 4 h later in an ELISA reader 
(450 nm vs. 650 nm). Each time point / concentration was 
measured in four technical replicates.
FACS-based propidium iodide and AnnexinV / 
7AAD measurement
For propidium iodide (PI) FACS cell cycle analysis, 
5x105 cells were washed once in PBS, centrifuged for 
5 min at 1000 rpm and fixed by re-suspending in 300 
μl PBS + 700 μl ice cold 100% ethanol. After 1 - 2h of 
fixation at -20°C, cells were pelleted by centrifugation (5 
min, 1000 rpm) and re-suspended in 1 ml DNA staining 
solution (PBS + 2 μl PI (1 mg/ml), + 20 μl RNAseA (10 
mg/ml)). After 15 min of incubation at RT under constant 
agitation samples were analyzed by FACS. First, the 
single cell population was identififed in a forward versus 
side scatter plot. Duplets or clumbs and cell debris was 
excluded from analyses. Next, cell cycle distribution was 
detected by a forward scatter versus PI plot and illustrated 
as a histogram by plotting PI versus cell. For apoptosis 
measurement, the ‘AnnexinV Apoptosis Detection Kit 
I’ was used (BD Biosciences, Heidelberg, Germany). 
Early and late apoptotic as well as viable cell populations 
were identified by plotting PE AnnexinV versus 7-AAD. 
Analysis was performed according to the manual. For each 
measurement, three independent samples were pooled. 
For PI and AnnexinV FACS, in total 50000 cells were 
measured using the FACSCanto machine and analyzed by 
the FACSDiva Software (BD Biosciences).
Illumina HT-12v4 expression microarray
The Illumina expression microarray analyses were 
performed exactly as published [14]. Briefly, RNA quality 
was checked in a BioAnalyzer 2100 (RNA 6000 nano lab 
chip) (Agilent Technologies, Waldbronn, Germany). Samples 
were processed on Illuminas human’ HT-12v4’ chips (San 
Diego, California, USA). Technical quality parameters such 
as hybridization, extension and specificity were evaluated 
using the ‘Genome Studio’ software. Expression values were 
quantile normalized using the ‘limma’-software-package 
(‘Linear Models for Microarray Data’, www.bioconductor.
org). The microarray data set is publically available via GEO 
(ncbi.nlm.nih.gov/geo/) (GSE71239).
Affymetrix expression microarray analysis of 
GCC tissues
The whole procedure and the microarray data have 
already been published [12]. The microarray data were 
re-analyzed in context of this study and includes normal 
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testis tissue (n = 4), GCNIS (n = 3), seminomas (N = 4), 
ECs (n = 3), teratomas (n = 3) and mixed non seminomas 
(n = 4). All tumors were classified according to the WHO 
classification of tumors based on their histology and 
assessment of tumor or GCNIS amount.
Chromatin-immunoprecipitation-followed-by-
sequencing
For chromatin-immunoprecipitation-followed-by-
sequencing (ChIP-seq) analysis, cells of interest were 
fixed by Formaldehyde solution (11% Formaldehyde, 
0.1 M NaCl, 1 mM EDTA (pH 8), 50 mM HEPES (pH 
7.9)) and further processed by Active Motif (Carlsbad, 
CA, USA), involving shearing of DNA by sonication, 
chromatin-immunoprecipitation, library generation and 
sequencing (NextSeq500, Illumina). Pooled input DNA 
of each sample including spike-in Drosophila DNA were 
used as controls and for normalization. The 75-nt sequence 
reads were mapped against the genome using BWA 
algorithm. Duplicate reads were removed. Only peaks that 
align with no more than 2 mismatches and map uniquely 
to the genome were used for further analysis. Intervals 
/ peaks were identified by the MACS peak finding 
algorithm (cutoff p-value 1x10-7) including ENCODE 
blacklist filtering [26]. ChIP-seq data was visualized using 
the ‘UCSC Genome Browser’ (www.genome-euro.ucsc.
edu). ChIP-seq data sets are publically available via GEO 
(GSE78262).
Xenotransplantation of TCam-2 and 2102EP 
cells
Xenotransplantation was performed as described in 
a previous publication [14]. 1x107 TCam-2 and 2102EP 
cells were re-suspended in 4°C cold 500 μl Matrigel (BD 
Biosciences) and injected into the right flank of nude mice 
using a pre-cooled 28G syringe (BD Biosiences). At the 
day of romidepsin application, the mice were weighted 
allowing for accurate calculation of the correct dosages. A 
romidepsin solution of desired concentration was prepared 
freshly. Nude mice were pre-warmed on a 37°C warm 
plate allowing for a more easy injection procedure due to 
enlarging of blood vessels. Afterwards, mice were fixed 
in a fixator and 100 μl of the romidepsin solution were 
injected intravenously into the vein of nude mice using 
a 28G syringe (BD Biosciences). For each experimental 
condition, three mice were analyzed. Animal experiments 
were conducted according to the German law of animal 
protection and in agreement with the approval of the 
local institutional animal care committees (Landesamt für 
Natur, Umwelt und Verbraucherschutz NRW (approval 
ID: AZ84-02.04.2013.A430)). The experiments were 
performed in accordance with the ‘International Guiding 
Principles for Biomedical Research Involving Animals’ as 
announced by the ‘Society for the Study of Reproduction’.
STRING analysis
STRING protein-interaction predictions were 
performed online using default settings (www.string-db.
org) [27].
ACKNOWLEDGMENTS
We kindly thank Blanca Randel, Yvonne 
Schleehuber, Angela Egert, Gaby Beine, and Martin 
Fellermeyer for technical assistance. Furthermore, we 
would like to thank Dr. Michael Peitz (Life & Brain, 
University Bonn Medical School, Bonn, Germany) for 
providing MPAF / ARZ / EMF cells and Dr. Andrea 
Hofmann as well as Dr. Per Hoffmann (Institute of 
Human Genetics, University Bonn Medical School, 
Bonn, Germany) for performing the Illumina expression 
microarrays.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest!
FUNDING
This study was supported by BONFOR and the DFG 
to DN (O-155.0065; NE 1861/3-1).
REFERENCES
1. Skakkebaek NE. Possible carcinoma-in-situ of the testis. 
Lancet. 1972; 2:516–7.
2. Oosterhuis JW, Looijenga LHJ. Testicular germ-cell 
tumours in a broader perspective. Nat Rev Cancer. 2005; 
5:210–22.
3. Berney DM, Looijenga L, Idrees M, Oosterhuis JW, 
Rajpert-De Meyts E, Ulbright TM, Skakkebaek NE. Germ 
Cell Neoplasia In Situ(GCNIS). Evolution of the Current 
Nomenclature for Testicular Pre-invasive Germ Cell 
Malignancy. Histopathology. 2016; :n/a–n/a.
4. Sonne SB, Almstrup K, Dalgaard M, Juncker AS, Edsgard 
D, Ruban L, Harrison NJ, Schwager C, Abdollahi A, Huber 
PE, Brunak S, Gjerdrum LM, Moore HD, et al. Analysis 
of Gene Expression Profiles of Microdissected Cell 
Populations Indicates that Testicular Carcinoma In situ Is 
an Arrested Gonocyte. Cancer Research. 2009; 69:5241–50.
5. Adami HO, Bergstrom R, Mohner M, Zatonski W, Storm 
H, Ekbom A, Tretli S, Teppo L, Ziegler H, Rahu M, et al. 
Testicular cancer in nine northern European countries. Int J 
Cancer. 1994; 59:33–8.
6. Hersmus R, de Leeuw BHCGM, Wolffenbuttel KP, Drop 
SLS, Oosterhuis JW, Cools M, Looijenga LHJ. New 
insights into type II germ cell tumor pathogenesis based on 
Oncotarget74946www.impactjournals.com/oncotarget
studies of patients with various forms of disorders of sex 
development (DSD). MOLECULAR AND CELLULAR 
ENDOCRINOLOGY. 2008; 291:1–10.
7. Cools M, Wolffenbuttel KP, Drop SLS, Oosterhuis JW, 
Looijenga LHJ. Gonadal development and tumor formation 
at the crossroads of male and female sex determination. 
Sexual development: genetics, molecular biology, 
evolution, endocrinology, embryology, and pathology of sex 
determination and differentiation. 2011; 5:167–80.
8. Koster R, di Pietro A, Timmer-Bosscha H, Gibcus JH, 
van den Berg A, Suurmeijer AJ, Bischoff R, Gietema JA, 
de Jong S. Cytoplasmic p21 expression levels determine 
cisplatin resistance in human testicular cancer. J Clin Invest. 
2010; 120:3594–605.
9. Nettersheim D, Gillis A, Biermann K, Looijenga LHJ, 
Schorle H. The seminoma cell line TCam-2 is sensitive to 
HDAC inhibitor depsipeptide but tolerates various other 
chemotherapeutic drugs and loss of NANOG expression. 
Genes Chromosom Cancer. Wiley Subscription Services, 
Inc., A Wiley Company; 2011; 50:1033–42.
10. Andrews PW, Damjanov I, Simon D, Banting GS, Carlin 
C, Dracopoli NC, Føgh J. Pluripotent embryonal carcinoma 
clones derived from the human teratocarcinoma cell line 
Tera-2. Differentiation in vivo and in vitro. Lab Invest. 
1984; 50:147–62.
11. Andrews PW, Fenderson B, Hakomori S. Human embryonal 
carcinoma cells and their differentiation in culture. 
International Journal of Andrology. 1987; 10:95–104.
12. Eckert D, Nettersheim D, Heukamp LC, Kitazawa S, 
Biermann K, Schorle H. TCam-2 but not JKT-1 cells 
resemble seminoma in cell culture. Cell and Tissue 
Research. Springer-Verlag; 2008; 331:529–38.
13. Port M, Glaesener S, Ruf C, Riecke A, Bokemeyer C, 
Meineke V, Honecker F, Abend M. Micro-RNA expression 
in cisplatin resistant germ cell tumor cell lines. Mol Cancer. 
BioMed Central Ltd; 2011; 10:52.
14. Nettersheim D, Jostes S, Sharma R, Schneider S, Hofmann 
A, Ferreira HJ, Hoffmann P, Kristiansen G, Esteller 
MB, Schorle H. BMP Inhibition in Seminomas Initiates 
Acquisition of Pluripotency via NODAL Signaling 
Resulting in Reprogramming to an Embryonal Carcinoma. 
PLoS Genet. 2015; 11:e1005415.
15. Schumacher V, Gueler B, Looijenga LHJ, Becker JU, 
Amann K, Engers R, Dotsch J, Stoop H, Schulz W, Royer-
Pokora B. Characteristics of testicular dysgenesis syndrome 
and decreased expression of SRY and SOX9 in Frasier 
syndrome. Mol Reprod Dev. 2008; 75:1484–94.
16. Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville 
E, Blagosklonny MV, Bates SE. P21-dependent g(1)arrest 
with downregulation of cyclin D1 and upregulation of 
cyclin E by the histone deacetylase inhibitor FR901228. 
British Journal of Cancer. 2000; 83:817–25.
17. Cayrol C, Knibiehler M, Ducommun B. p21 binding to 
PCNA causes G1 and G2 cell cycle arrest in p53-deficient 
cells. Oncogene. 1998; 16:311–20.
18. Reisman D, Glaros S, Thompson EA. The SWI/SNF 
complex and cancer. Oncogene. 2009; 28:1653–68.
19. Gao X, Tate P, Hu P, Tjian R, Skarnes WC, Wang Z. ES cell 
pluripotency and germ-layer formation require the SWI/
SNF chromatin remodeling component BAF250a. Proc Natl 
Acad Sci U S A. 2008; 105:6656–61.
20. Keenen B, la Serna de IL. Chromatin remodeling in 
Embryonic stem cells: Regulating the balance between 
pluripotency and differentiation. J Cell Physiol. 2009; 
219:1–7.
21. Liebermann DA, Hoffman B. Gadd45 in stress signaling. 
JMS. 2014; 3:15–8.
22. Liu C, Shi Y, Du Y, Ning X, Liu N, Huang D, Liang J, Xue 
Y, Fan D. Dual-specificity phosphatase DUSP1 protects 
overactivation of hypoxia-inducible factor 1 through 
inactivating ERK MAPK. Experimental Cell Research. 
2005; 309:410–8.
23. Lu Z, Xu S. ERK1/2 MAP kinases in cell survival and 
apoptosis. IUBMB Life (International Union of Biochemistry 
and Molecular Biology: Life). 2006; 58:621–31.
24. Chen B, Zhang W, Gao J, Chen H, Jiang L, Liu D, Cao Y, 
Zhao S, Qiu Z, Zeng J, Zhang S, Li W. Downregulation 
of ribosomal protein S6 inhibits the growth of non-small 
cell lung cancer by inducing cell cycle arrest, rather than 
apoptosis. Cancer Letters. 2014; 354:378–89.
25. Nettersheim D, Heimsoeth A, Jostes S, Schneider S, 
Fellermeyer M, Hofmann A, Schorle H. SOX2 is essential 
for in vivo reprogramming of seminoma-like TCam-2 cells 
to an embryonal carcinoma-like fate. Oncotarget. 2016; 
7:47095–47110. doi: 10.18632/oncotarget.9903.
26. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, 
Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W, Liu 
XS. Model-based analysis of ChIP-Seq (MACS). Genome 
Biol. 2008; 9:R137.
27. Szklarczyk D, Franceschini A, Wyder S, Forslund K, 
Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos 
A, Tsafou KP, Kuhn M, Bork P, Jensen LJ, et al. STRING 
v10: protein-protein interaction networks, integrated over 
the tree of life. Nucleic Acids Research. 2015; 43:D447–52.
